Episode Details

We love to hear from our listeners. Send us a message.

Ever wondered how a PhD project can evolve into a groundbreaking biotech business? Meet Dr. Eric Kazanet and Sophia Lugo, who turned their fascination with CRISPR and mRNA control into a revolutionary RNA therapeutics company. In this episode, you'll uncover how their pioneering technology promises to precisely target cells, potentially transforming genetic medicine. Eric's journey from Stanford to startup success will illuminate the intricate process of developing RNA therapies that could change patient care forever.

What does it take to build a successful biotech partnership? Eric and Sophia's story is a testament to the importance of trust, value alignment, and effective communication. Hear firsthand how Eric’s methodical vetting process and Sophia’s proactive stakeholder engagement set the stage for their venture. Their experiences offer invaluable lessons on navigating the high-stakes environment of a startup, emphasizing the critical role of shared vision and mutual respect in achieving business success.

Get ready to be inspired by the power of networking in biotech innovation. Eric and Sophia's journey highlights how a diverse and experienced network can be a game-changer, providing insights from industry leaders and mentors. We'll also cover the latest advancements in mRNA therapeutics and explore the complexities of funding and regulatory strategies. This episode is packed with rich conversations about the challenges and opportunities in RNA therapeutics, promising to deliver new, targeted treatments to patients who need them most.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/